- Sandoz confirms European Commission approval of Pyzchiva® (ustekinumab), further strengthening immunology offering
- Sandoz opens new antibiotic production facility in Austria, to significantly increase capacity for life-saving medicines
- Sandoz reports fourth quarter 2023 sales and full-year 2023 results
- Sandoz receives FDA approval for first and only denosumab biosimilars
- Sandoz announces nominations to the Board of Directors and leadership change
- Sandoz acquires CIMERLI® business from Coherus, further building biosimilar and ophthalmology leadership in US market
- Sandoz US subsidiaries resolve generic drug antitrust class action litigation with direct purchaser class plaintiffs
- Sandoz announces changes in the Board of Directors
- Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in Germany
- Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
More ▼
Key statistics
On Friday, Sandoz Group AG (SDZ:SWX) closed at 30.00, -5.12% below its 52-week high of 31.62, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 30.81 |
---|---|
High | 30.90 |
Low | 29.71 |
Bid | 30.00 |
Offer | 30.00 |
Previous close | 30.71 |
Average volume | 2.14m |
---|---|
Shares outstanding | 431.00m |
Free float | 395.66m |
P/E (TTM) | -- |
Market cap | 12.96bn CHF |
EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Apr 26 2024 16:33 BST.
More ▼